OTCM
NMRD
Market cap4kUSD
Oct 06, Last price
0.00USD
1D
0.00%
Jan 2017
-100.00%
IPO
-100.00%
Name
Nemaura Medical Inc
Chart & performance
P/E
—
P/S
0.05
EPS
—
Div yield, %
—
Shrs. gr., 5y
-30.19%
Rev. gr., 5y
%
Revenues
77k
-84.71%
Net income
-14m
L+1.85%
CFO
-8m
L+29.95%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Nemaura Medical Inc. is a medical technology company dedicated to inventing, developing, and bringing to market diagnostic medical devices. Its flagship product, sugarBEAT, is an innovative, non-invasive continuous glucose monitoring (CGM) system. This device is designed to assist individuals with Type 1 and Type 2 diabetes in managing their condition, and it can also screen for pre-diabetic states. Beyond this, Nemaura offers proBEAT, a wellness guidance service that delivers educational prompts to users about factors influencing their blood sugar profiles. The company also conducts specialized programs aimed at diabetes prevention and reversal. Established in 2009, Nemaura Medical Inc. operates from its headquarters in New York City.
Related entities
Subsidiaries
DERMAL DIAGNOSTICS LIMITED
Key people
Chris Avery
Vice President - Global Business Operations · since 2019
Dewan Fazlul Hoque Chowdhury
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer · since 2019
Bashir Timol
Director, Chief Business Officer · since 2018
Timothy Johnson
Independent Director · since 2017
Thomas Moore
Independent Director · since 2017
Salim Natha
Independent Director · since 2017
Headquarters & legal address
c/o CORPORATE CREATIONS NETWORK INC., 8275 SOUTH EASTERN AVENUE #200
Las Vegas, NV 89123
US
Las Vegas, NV 89123
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||